Application Note
Pharmacological Validation of Alzheimer’s Disease Panel: Biomarker Selection and Profiling of Neuroprotective Compounds
Profile compound response in iPSC neurons from 10 sporadic Alzheimer's donors, drawn from a 14-line APOE-genotyped panel, combining Aβ40 and Aβ42 ELISA dose response with baseline RNA-seq molecular subtyping.
Download Your Application Note
"*" indicates required fields
We respect your inbox. You can unsubscribe at any time. View our privacy policy.
Inside This Application Note
Review how a 14-line Alzheimer's iPSC neuron panel was used to profile two clinically tested compounds by amyloid ELISA, and how baseline transcriptomics revealed a pattern in which donor lines responded.
- Elenbecestat lowered both Aβ42 and Aβ40 in essentially every line tested, establishing clear target engagement.
- ABT-089, which showed no benefit in its Phase 2 trial, produced an apparent reduction in the Aβ42/Aβ40 ratio in only three lines, with the rest clustering near baseline.
- Baseline RNA-seq and clustering analysis sorted the AD donors into four molecular subtypes, and all three responders shared one.
Related Resources
Explore related cell models, services, and protocols connected to this application.